|Articles|July 5, 2023
New FDA Draft Guidance Shows That the Time for Decentralized Clinical Trials is Now.
Author(s)Science 37
On May 1, 2023, the U.S. Food and Drug Administration (FDA) released an updated Draft Guidance on decentralized trials. This release shows that the landscape of clinical research is rapidly evolving. The shift towards decentralized clinical trials presents an exciting opportunity for sponsors to improve patient engagement, enhance data quality, and accelerate clinical research. Are you prepared for what’s to come? Download the insight brief to learn more.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
The Evolution of Global Trial Strategies in Today's Complex Healthcare Landscape
2
The Business Case for DEI in Pharmaceutical Innovation: Why Organizational Commitment Matters for Inclusive Clinical Trials
3
Centering Site Experience to Accelerate Study Activation
4
ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships
5